I am a
Home I AM A Search Login

Papers of the Week


2022 Jul 01


Curr Opin Ophthalmol


33


4

Pilocarpine 1.25% and the changing landscape of presbyopia treatment.

Authors

Meghpara BB, Lee JK, Rapuano CJ, Mian SI, Ho AC
Curr Opin Ophthalmol. 2022 Jul 01; 33(4):269-274.
PMID: 35779051.

Abstract

Despite affecting approximately 1.8 billion individuals worldwide, until recently, a pharmacologic treatment for presbyopia was not available. This special commentary reviews the treatment of presbyopia with a focus on the recently approved medication Vuity (pilocarpine 1.25%, Allergan, an AbbVie Company).